Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation
Frontiers in PharmacologyCoronary microvascular disease (CMVD) has emerged as a new target for the occurrence and development of heart failure treatment. Various indicators such as Index of Microvascular Resistance, Coronary Flow Reserve, Microvascular Resistance Reserve ...
Shaoxin Chen +5 more
doaj +5 more sources
Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews [PDF]
Journal of Cardiovascular Development and DiseaseBackground: Several studies have shown that sodium-dependent glucose transporter 2 inhibitors can be used in the treatment of heart failure. This article summarized systematic reviews of sodium-dependent glucose transporter 2 inhibitors in the treatment ...
Yixuan Fang +3 more
doaj +2 more sources
Sodium-glucose co-transporter 2 inhibitors – a review article
Journal of Education, Health and Sport, 2019 Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus.
Marcin Makuch +3 more
doaj +5 more sources
Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease [PDF]
The Scientific World Journal, 2015 SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced.
L. Zanoli +6 more
doaj +4 more sources
Sodium glucose co-transporter 2 inhibitors in heart failure therapy
Türk Kardiyoloji Derneği Arşivi, 2020 Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are a new class of drugs for patients with type 2 diabetes (T2DM) which inhibit urinary glucose reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis.
Yüksel Çavuşoğlu +10 more
doaj +4 more sources
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Frontiers in Pharmacology, 2022 Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life.
Yuling Jing +3 more
doaj +3 more sources
Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
Perspectives in Clinical Research, 2021 Cardiovascular outcome trials (CVOTs) have to be done by sponsors who wish to launch new antidiabetic drugs in the US, since the December 2008 US Food and Drug Administration ruling, which was subsequently accepted by the European Medicines (Evaluation ...
Viraj Ramesh Suvarna
doaj +4 more sources
Advances in sodium-glucose transporter protein 2 inhibitors and tumors
Frontiers in OncologyTumor is a major challenge to global health and has received extensive attention worldwide due to its high degree of malignancy and poor prognosis. Although the clinical application of targeted therapy and immunotherapy has improved the status quo of ...
Jiaqi Wang, Wenyong Yang
doaj +3 more sources
Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes
Therapeutic Advances in Endocrinology and Metabolism, 2014 Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets.
Bernard Peene, Katrien Benhalima
doaj +2 more sources
The Impact of Sodium Glucose Transporter 2 Inhibitors on Renal Parenchymal Oxygenation [PDF]
Kidney360Samuel N. Heyman, Zaid Abassi
doaj +2 more sources